【藥品庫存】 根據中央疫情指揮中心公告，非公費對象自費購買，請下載申請書、開立審查表填寫後交給批價櫃檯，經繳費後，始能調劑領藥。

Adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization.

Antiviral Agent. A SARS-CoV-2 nucleotide analog RNA polymerase inhibitor, , which is essential for viral replication.

Protein binding: 88% to 93.6%
.Half-life elimination: ~1 hour
Excretion:
1. Urine: 10%
2. Feces: Not detected

Hypersensitivity to remdesivir or any component of the formulation.

C

It is not known if remdesivir is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk and benefits.

Skin rash, nausea, prolonged prothrombin time, increased serum ALT and AST, hypersensitivity reaction, seizure
Postmarketing: Bradycardia, cardiac failure, hypotension, severe bradycardia

COVID-19, hospitalized patients:
Infants and Children <12 years
3.5 to <40 kg: Lyophilized powder only: IV: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg/dose once daily.
≥40 kg: Lyophilized powder only: IV: Loading dose: 200 mg on day 1, followed by 100 mg once daily.
Children 12 years and Adolescents
<40 kg: Lyophilized powder only: IV: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg/dose once daily.
≥40 kg: Injection solution or lyophilized powder: IV: Loading dose: 200 mg on day 1, followed by 100 mg once daily.
Duration:
Duration is generally 5 days or until hospital discharge, whichever is first, but may extend up to 10 days in certain hospitalized patients .

eGFR >30 mL/minute: No dosage adjustment necessary.
eGFR <30 mL/minute: Use is not recommended.

There are no dosage adjustments provided in the manufacturers labeling (has not been studied). Hepatoxicity during therapy:
1. ALT >10 times the ULN: Consider remdesivir discontinuation.
2. ALT elevation AND signs or symptoms of liver inflammation: Discontinue remdesivir.

VEKLURY contains no preservative.